Volume 19, Number 7—July 2013
Dispatch
Multidrug-Resistant Atypical Variants of Shigella flexneri in China
Table 2
Antimicrobial drug | % Resistant isolates |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
X variant (−:7,8, E1037), indole-negative variety, n = 73 |
Serotype 2 variant (II:3,4,7,8), n = 17 |
Untypeable variant (−:E1037), n = 2 |
|||||||||||||
R | I | S | R | I | S | R | I | S | |||||||
Ampicillin | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
Ampicillin/sulbactam | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
Chloramphenicol | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
Nalidixic acid | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
Tetracycline | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
Amoxicillin/clavulanic acid | 91.8 | 5.5 | 2.7 | 88.2 | 0 | 11.8 | 100.0 | 0 | 0 | ||||||
Trimethoprim/sulfa | 90.4 | 0 | 9.6 | 58.8 | 0 | 41.2 | 100.0 | 0 | 0 | ||||||
Norfloxacin | 82.2 | 16.4 | 1.4 | 29.4 | 0 | 70.6 | 100.0 | 0 | 0 | ||||||
Ciprofloxacin | 39.7 | 49.3 | 11.0 | 29.4 | 0 | 70.6 | 100.0 | 0 | 0 | ||||||
Levofloxacin | 21.9 | 26.0 | 52.1 | 17.6 | 11.8 | 70.6 | 0 | 50.0 | 50.0 | ||||||
Cefotaxime | 13.7 | 13.7 | 72.6 | 17.6 | 5.9 | 76.5 | 0 | 0 | 100.0 | ||||||
Gentamicin | 6.8 | 0 | 93.2 | 5.9 | 0 | 94.1 | 0 | 0 | 100.0 | ||||||
Ceftazidime | 5.5 | 2.7 | 91.8 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | ||||||
Imipenem | 2.7 | 0 | 97.3 | 0 | 0 | 100.0 | 0 | 0 | 100.0 |
*R, resistant; I, intermediate; S, susceptible.
1These authors contributed equally to this article.
Page created: June 06, 2013
Page updated: June 06, 2013
Page reviewed: June 06, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.